Actively Recruiting

Phase Not Applicable
Age: 16Years +
All Genders
Healthy Volunteers
NCT05878483

Autonomous Blood Drawing Optimization and Performance Testing

Led by Vitestro B.V. · Updated on 2026-04-07

44658

Participants Needed

5

Research Sites

336 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device). The study consists of several phases (A, B1, B2, C1, C2, C3, 0). Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing. Phases A, B2, B3, C1, C2, C3 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection). The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers can be included in a non-hospital site (Vitestro Site).

CONDITIONS

Official Title

Autonomous Blood Drawing Optimization and Performance Testing

Who Can Participate

Age: 16Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 16 years
Not Eligible

You will not qualify if you...

  • Unable to follow instructions due to mental disability or incapacity
  • Unable to use the device correctly due to physical impairment or disability such as severe contractures or deformities
  • No venipuncture possible in the cubital fossa of both arms due to reasons like amputation or tattoos
  • Incapacitated persons
  • Pregnant or breastfeeding
  • Arteriovenous fistula or vascular graft in the arm
  • Paretic or paralyzed arm (e.g., after stroke or trauma)
  • Infected skin in the cubital fossa (e.g., erysipelas or cellulitis)
  • Mastectomy side or axillary lymph node removed
  • Healed skin burns in the cubital fossa
  • Edema in the cubital fossa
  • Extensive scarring in the cubital fossa
  • Hematoma in the cubital fossa
  • Tattoos in the cubital fossa
  • Patients with contraindications in one arm are excluded from Phases B2 and B3 where venipunctures are performed on both arms

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

OLVG Lab

Amsterdam, North Holland, Netherlands, 1091 AC

Actively Recruiting

2

Amsterdam UMC

Amsterdam, North Holland, Netherlands, 1105 AZ

Actively Recruiting

3

Result Laboratorium, location Albert Schweitzer Hospital

Dordrecht, South Holland, Netherlands, 3318 AT

Actively Recruiting

4

St. Antonius Hospital

Nieuwegein, Utrecht, Netherlands, 3435CM

Actively Recruiting

5

Vitestro

Utrecht, Utrecht, Netherlands, 3526KS

Not Yet Recruiting

Loading map...

Research Team

L

Luuk Giesen, MD

CONTACT

J

Jeroen Roest, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here